200 related articles for article (PubMed ID: 27641080)
21. Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).
Manuchehri AM; Sathyapalan T; Lowry M; Turnbull LW; Rowland-Hill C; Atkin SL
Pituitary; 2007; 10(3):261-6. PubMed ID: 17557207
[TBL] [Abstract][Full Text] [Related]
22. Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy.
Delgrange E; Duprez T; Maiter D
Clin Endocrinol (Oxf); 2006 Apr; 64(4):456-62. PubMed ID: 16584520
[TBL] [Abstract][Full Text] [Related]
23. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.
Hu J; Zheng X; Zhang W; Yang H
Pituitary; 2015 Oct; 18(5):745-51. PubMed ID: 25500765
[TBL] [Abstract][Full Text] [Related]
24. Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas.
George LD; Nicolau N; Scanlon MF; Davies JS
Clin Endocrinol (Oxf); 2000 Nov; 53(5):595-9. PubMed ID: 11106920
[TBL] [Abstract][Full Text] [Related]
25. Does hypopituitarism recover when macroprolactinomas are treated with cabergoline?
Karavitaki N; Dobrescu R; Byrne JV; Grossman AB; Wass JA
Clin Endocrinol (Oxf); 2013 Aug; 79(2):217-23. PubMed ID: 23215960
[TBL] [Abstract][Full Text] [Related]
26. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients.
Vroonen L; Jaffrain-Rea ML; Petrossians P; Tamagno G; Chanson P; Vilar L; Borson-Chazot F; Naves LA; Brue T; Gatta B; Delemer B; Ciccarelli E; Beck-Peccoz P; Caron P; Daly AF; Beckers A
Eur J Endocrinol; 2012 Nov; 167(5):651-62. PubMed ID: 22918301
[TBL] [Abstract][Full Text] [Related]
27. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
[TBL] [Abstract][Full Text] [Related]
28. Falsely low serum prolactin in two cases of invasive macroprolactinoma.
Schöfl C; Schöfl-Siegert B; Karstens JH; Bremer M; Lenarz T; Cuarezma JS; Samii M; von zur Mühlen A; Brabant G
Pituitary; 2002; 5(4):261-5. PubMed ID: 14558675
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of short-term maintenance treatment with cabergoline in microadenoma-related and idiopathic hyperprolactinemia.
Buyukbayrak EE; Karageyim Karsidag AY; Kars B; Balcik O; Pirimoglu M; Unal O; Turan C
Arch Gynecol Obstet; 2010 Nov; 282(5):561-6. PubMed ID: 20571820
[TBL] [Abstract][Full Text] [Related]
30. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.
Sala E; Bellaviti Buttoni P; Malchiodi E; Verrua E; Carosi G; Profka E; Rodari G; Filopanti M; Ferrante E; Spada A; Mantovani G
J Endocrinol Invest; 2016 Dec; 39(12):1377-1382. PubMed ID: 27245604
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
Primeau V; Raftopoulos C; Maiter D
Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
[TBL] [Abstract][Full Text] [Related]
32. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy.
Kharlip J; Salvatori R; Yenokyan G; Wand GS
J Clin Endocrinol Metab; 2009 Jul; 94(7):2428-36. PubMed ID: 19336508
[TBL] [Abstract][Full Text] [Related]
33. Drug treatment of hyperprolactinemia.
Chanson P; Borson-Chazot F; Chabre O; Estour B
Ann Endocrinol (Paris); 2007 Jun; 68(2-3):113-7. PubMed ID: 17532288
[TBL] [Abstract][Full Text] [Related]
34. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma.
Cannavò S; Curtò L; Squadrito S; Almoto B; Vieni A; Trimarchi F
J Endocrinol Invest; 1999 May; 22(5):354-9. PubMed ID: 10401709
[TBL] [Abstract][Full Text] [Related]
35. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients.
Delgrange E; Daems T; Verhelst J; Abs R; Maiter D
Eur J Endocrinol; 2009 May; 160(5):747-52. PubMed ID: 19223454
[TBL] [Abstract][Full Text] [Related]
36. [Current diagnosis and treatment of hyperprolactinemia].
Melgar V; Espinosa E; Sosa E; Rangel MJ; Cuenca D; Ramírez C; Mercado M
Rev Med Inst Mex Seguro Soc; 2016; 54(1):111-21. PubMed ID: 26820213
[TBL] [Abstract][Full Text] [Related]
37. Cabergoline as a first-line treatment in newly diagnosed macroprolactinomas.
Pontikides N; Krassas GE; Nikopoulou E; Kaltsas T
Pituitary; 2000 May; 2(4):277-81. PubMed ID: 11081149
[TBL] [Abstract][Full Text] [Related]
38. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia.
Colao A; Sarno AD; Cappabianca P; Briganti F; Pivonello R; Somma CD; Faggiano A; Biondi B; Lombardi G
Eur J Endocrinol; 2003 Mar; 148(3):325-31. PubMed ID: 12611613
[TBL] [Abstract][Full Text] [Related]
39. Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study.
Nachtigall LB; Valassi E; Lo J; McCarty D; Passeri J; Biller BM; Miller KK; Utz A; Grinspoon S; Lawson EA; Klibanski A
Clin Endocrinol (Oxf); 2010 Jan; 72(1):53-8. PubMed ID: 19508591
[TBL] [Abstract][Full Text] [Related]
40. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline.
Biller BM; Molitch ME; Vance ML; Cannistraro KB; Davis KR; Simons JA; Schoenfelder JR; Klibanski A
J Clin Endocrinol Metab; 1996 Jun; 81(6):2338-43. PubMed ID: 8964874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]